2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2009
A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?
Enestvedt C, Diggs B, Shipley D, Thomas C, Billingsley K. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointestinal Cancer Research : GCR 2009, 3: 233-8. PMID: 21151426, PMCID: PMC3000069.Peer-Reviewed Original ResearchReceipt of chemoradiotherapyAdjuvant therapyAdjuvant chemoradiotherapyIndependent predictorsGastric adenocarcinomaGastric cancerResectable gastric adenocarcinomaModest survival benefitAmerican Joint CommitteeCurrent practice patternsState Cancer RegistryStandard of carePopulation-based analysisAnalysis of survivalGastric cancer treatmentChi-square testBinary logistic regressionEligible patientsN2 diseaseTreatment eraResection typeSurvival benefitLymph nodesAJCC stageCancer RegistryOxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)
Leichman L, Goldman B, Benedetti J, Billingsley K, Thomas C, Iqbal S, Lenz H, Blanke C, Gold P, Corless C. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). Journal Of Clinical Oncology 2009, 27: 4513-4513. DOI: 10.1200/jco.2009.27.15_suppl.4513.Peer-Reviewed Original ResearchExternal beam radiationPathologic complete responsePhase II trialOverall survivalEsophageal adenocarcinomaII trialSouthwest Oncology Group phase II trialGrade 3/4 toxicitiesMedian overall survivalNon-hematologic toxicitiesCentral pathology reviewPrimary tumor responseCooperative group trialsStandard of careTumor molecular profilesAcceptable toxicityFree survivalModality therapyComplete responseGastric cardiaNew regimensPathology reviewFuture trialsTumor responseSitu cancer